Gilead Sciences falls after quarterly sales miss estimates

** Shares of drugmaker Gilead Sciences GILD.O fall 3.4% to $102.59 in extended trading

** Company reports Q1 sales of $6.67 bln, below analysts' estimates of $6.81 bln, according to data compiled by LSEG

** Sales of company's cancer drug, Trodelvy, fell 5% to $293 mln

** Sales of company's COVID-19 antiviral, Veklury, fell 45% to $302 mln

** However, company reports Q1 adj. profit of $1.81/shr, above analysts' estimates of $1.79/shr

** As of last close, stock up 14.8% YTD